


PATENT

I hereby certify that the correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Mail Stop DD, P.O. Box 1450, Alexandria, VA, 22313-1450, on January 7, 2004.

 1/7/03
Ginger M. Graff Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No.: 10/669,490
Filing Date: September 24, 2003
Applicant(s): Gilbert R. Gonzales, et al.
Title: **ORAL TRANSMUCOSAL METHADONE**
Group Art Unit: 1614
Examiner: Unknown
Conf. No: 3979
Atty Docket No: XANO-41

Cincinnati, Ohio

January 7, 2004

Commissioner for Patents
Mail Stop DD
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
FILED PURSUANT TO 37 CFR §§ 1.56 AND 1.97-1.98

Sir:

In accordance with the duty of candor and good faith imposed by 37 C.F.R. §1.56, and the means of complying with that duty according to 37 C.F.R. §§1.97 and 1.98, the Applicants call the references listed on the attached form PTO-1449 to the attention of the United States Patent and Trademark Office in connection with the above-identified patent application. An Information Disclosure Statement with U.S.

patents is being electronically filed on even date herewith. The Applicants have enclosed a copy of all other cited references.

Applicants make no admission that the cited art represents the prior art or that the cited art is the most material art. Nonetheless, the Examiner is urged to consider the cited references and to make an independent decision with respect to the materiality thereof.

No fee is believed due in connection with this submission. However, if such fees are necessary, the Commissioner is authorized to charge any necessary fees to Deposit Account 23-3000.

Respectfully submitted,

WOOD, HERRON & EVANS, L.L.P.

By: G. Prabhakar Reddy
G. Prabhakar Reddy, Reg. No. 47,890

Wood, Herron & Evans, L.L.P.
2700 Carew Tower
Cincinnati, OH 45202
(513) 241-2324 (voice)
(513) 421-7269 (facsimile)

SUBSTITUTE FORM PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
XANO/41SERIAL NO.
10/669,490INFORMATION DISCLOSURE
STATEMENT BY APPLICANTAPPLICANT
Gonzales, et al.FILING DATE
September 24, 2003GROUP
1614

(37 CFR 1.98(b))

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A.A						
	A.B						
	A.C						
	A.D						
	A.E						
	A.F						
	A.G						
	A.H						
	A.I						
	A.J						
	A.K						

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

	DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
A.L	EP0430149	11/26/90	EP			no
A.M						
A.N						
A.O						
A.P						
A.Q						

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

A.R	Author unknown, <u>About ACTIQ</u> , www.actiq.com/patients/aboutactiq/default.asp , July 7, 2003, 2 pgs.
A.S	Author unknown, <u>Drugs Approved by the FDA</u> , Drug Name: Actiq, www.centerwatch.com/patient/drugs/dru495.html , July 7, 2003, 2 pgs.
A.T	Eleanor Chuang, et al., <u>Fentanyl Oralet®</u> , website Fentanyl Oralet.doc, April 19, 2003, 11 pgs.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.